Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
about
Epigenetic treatment of solid tumours: a review of clinical trialsHistone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerHDAC8 substrates: Histones and beyondHistone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsHealth promoting effects of brassica-derived phytochemicals: from chemopreventive and anti-inflammatory activities to epigenetic regulationMutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemiaCombined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumorsFenretinide causes emphysema, which is prevented by sphingosine 1-phoshate.Identification of an intrinsic determinant critical for maspin subcellular localization and function.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Histone Deacetylase 3 and 4 Complex Stimulates the Transcriptional Activity of the Mineralocorticoid Receptor.Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.Truth and consequences of sphingosine-1-phosphate lyase.The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.Tamoxifen Action in ER-Negative Breast Cancer.Inhibition of HDAC2 protects the retina from ischemic injury.Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Class I lysine deacetylases facilitate glucocorticoid-induced transcription.The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expressionp53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors.Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cellsHistone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.Molecular hallmarks of adult T cell leukemia.The role of hypoxia in pulmonary vascular diseases: a perspective.Metal-dependent Deacetylases: Cancer and Epigenetic RegulatorsInhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing AutophagyInfluenza A Virus Dysregulates Host Histone Deacetylase 1 That Inhibits Viral Infection in Lung Epithelial CellsImpact of acetylation on tumor metabolism.Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.Chromatin remodeling: a new landscape to treat harmful alcohol-use disorders.Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.Chromatin remodeling--a novel strategy to control excessive alcohol drinking.Controlling Epithelial to Mesenchymal Transition through Acetylation of Histone H2BK5.Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.
P2860
Q26773803-054F8146-E7B4-4312-90EA-1B4649D180F9Q26777453-4C52163A-9797-4148-BABA-51B2098D6F60Q26824122-BF61CF2B-38EA-4909-B9BF-39C2B17F24E6Q26863429-069747AC-EB0A-46D8-903F-F3D0049CAD8BQ27015931-85CAB46A-11D7-4A1A-BDAF-9416B3E9C3D4Q28393960-74133288-B483-421E-BE4E-50490331F758Q33594629-EE76D405-4BBB-4DB2-AEEB-C008419D187DQ34372994-6D8B6D68-AB32-491F-A94B-CDF73A4628C9Q34551954-D84E898D-5C88-4C2B-B9B1-4757EFDC54D5Q35053115-020FFE66-E1E0-4416-9527-9740BB14D8B3Q35108007-D8768C40-CDFB-4CCA-9FA2-EF394B92C6A5Q35754734-F5075366-70A3-440A-8E57-AAA83B3A389FQ35822102-5328A9E4-0B26-4A00-B765-28AE0997E2E3Q36575961-D96435FE-D9EE-4772-9CF8-AF903FCED4E3Q36579794-DD2F651F-CAF3-4BF0-B7C9-B5A823684CC2Q36688302-87C7C72C-781E-4065-AE51-BBEFDB76B764Q36926069-E2604D2E-B03E-4ADB-97D2-156E72E2FF4AQ37027060-9A10A83E-AC91-45FA-AF97-413A1C3CF1CEQ37121662-03E98C07-1538-411C-9008-9F9A4B395AC5Q37213852-503CA59D-CCF2-474A-92E1-DF32DA7647A4Q37380311-6FA1EEC9-A796-4C6C-8C9B-F2BE5407B4A4Q37405258-42F331EC-91B4-4428-8751-C73A16D4662BQ37558978-7AABF464-93D4-48D6-BCFB-9EF56C7AE737Q37586906-5FD757E0-A20D-4FD8-B3B6-3BF18A670A65Q37589245-0137DA19-4C81-4BFF-B7A7-E9D5E0D56EE1Q38051633-BBAC4D7A-7C63-4610-B34D-69764BE91E38Q38078782-2A47FD8E-5903-476F-ABEF-8AB2D3F1DAD0Q38747135-9B514581-D9BB-4FC2-81BA-A85AFF12E731Q38760399-A15D168F-20E3-4883-B211-F01C0D0A5A64Q38791236-1D4F45EC-7AEB-4B43-9EA5-CD450BB35046Q38866711-5390E170-4C46-428A-B7D4-EBE47A1EC491Q38877252-3877DA9C-1411-4D9C-8DB9-9B04DEB098A5Q39011776-63C0AE4F-A8B4-465D-B4F2-9D41A502B52AQ39317758-BD0A920A-2BFB-4254-97D9-3A412523D6B1Q39785574-886EE49A-47EC-4F66-81E5-FFFE03AEDF18Q41147018-7988B82F-FF10-4035-AE3E-B00A894F574DQ41488932-3BB03BF3-2524-4C5B-8407-8CCAFEF391EAQ41722060-4AC46F6C-AE91-491E-9942-555CFF38C622Q41872120-68172844-D6AE-4E02-B0FC-5B480AEEEFF3Q48610578-3ECD94CC-6150-4F89-8C9B-A4B70047B9D3
P2860
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@ast
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@en
type
label
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@ast
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@en
prefLabel
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@ast
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@en
P2093
P2860
P356
P1433
P1476
Endogenous modulators and phar ...... eacetylases in cancer therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2011.267
P407
P577
2011-07-04T00:00:00Z